BioNTech’s High-Stakes Week: A Shot at a First Cancer Approval and the Autumn Vaccine Formula

BioNTech unveils promising pumitamig lung cancer data at ASCO while FDA panel decides on next Covid vaccine strain, as quarterly losses widen and stock slides.

BioNTech enters a defining week as it simultaneously unveils clinical data at the American Society of Clinical Oncology meeting in Chicago and awaits a critical vote from a US Food and Drug Administration advisory panel on the strain composition of the next Covid-19 shot. The twin events – one squarely in oncology, the other in its legacy vaccine business – come against a backdrop of widening losses and a stock that has drifted roughly 21% below its 52-week high.

The company reported a first-quarter net loss of €622 million on revenue of just €138 million, as sales of its Comirnaty vaccine continued to fade. Research and development spending surged to around €652 million, with the bulk directed toward its most advanced oncology assets, pumitamig and gotistobart. Despite the cash burn, BioNTech maintains a liquidity cushion of €19.6 billion as of March 31, and a share buyback programme of up to €1 billion over twelve months remains in place. Management has held its full-year revenue guidance at €2.3?billion to €2.6?billion.

At ASCO, which runs through 2 June, the spotlight falls on pumitamig, a bispecific immunomodulator combining PD-L1 checkpoint inhibition with VEGF-A neutralisation, developed in partnership with Bristol?Myers?Squibb. Fresh data from the phase?2/3 ROSETTA Lung-02 trial show encouraging antitumor activity in first-line non-small cell lung cancer. This marks the third consecutive global dataset with consistent signals, following earlier readouts in small-cell lung cancer and triple-negative breast cancer. The results are expected to inform the design of an ongoing phase?3 head-to-head study against pembrolizumab plus chemotherapy.

A more tangible regulatory milestone could arrive later this year. BioNTech and its partner DualityBio plan to submit a Biologics License Application to the FDA for trastuzumab pamirtecan in 2026, pending regulatory feedback. The antibody-drug conjugate already holds fast-track and breakthrough therapy designations for recurrent endometrial cancer. In a phase?2 trial of heavily pretreated HER2-expressing patients, it delivered a confirmed objective response rate of 47.9% across all HER2 levels; among those with HER2 IHC?3+ – the highest expression group – the response rate exceeded 70%. Median progression-free survival stood at 8.1 months. A successful filing would represent BioNTech’s first oncology approval in the United States.

On the vaccine front, the FDA’s Vaccines and Related Biological Products Advisory Committee will convene virtually on Thursday from 14:30 to 22:30 CET. The core question for the vote is whether the JN.1-lineage variant XFG should be recommended as the preferred strain for an updated monovalent vaccine for the 2026-2027 season. An alternative, BA.3.2, from a different lineage, is also under consideration. FDA briefing documents note that the previously dominant LP.8.1 subvariant has been displaced by newer JN.1 descendants such as XFG, which carry additional amino acid changes that could reduce antibody binding from current vaccines. The agency has indicated that an update is warranted, and all licensed manufacturers, including Pfizer-BioNTech, have signalled they can produce an XFG-based shot for the autumn. Pfizer-BioNTech is scheduled to present its own data between 17:20 and 17:40, alongside presentations from Moderna, Sanofi, the CDC and the WHO.

Investor reaction so far has been muted. BioNTech’s US-listed shares ended Wednesday at roughly $93, up 0.8%, and are down about 3% since the start of the year. The stock remains below its 50-day moving average, and the 52-week high of €101.90 – set last June – still looks distant. For the remainder of the year, BioNTech plans to initiate six additional phase?3 trials and expects seven late-stage data readouts. This week’s ASCO presentations and the FDA vaccine vote are merely the opening acts in a long pipeline calendar.